Boundless Bio, Inc. (BOLD) stock
BOLDNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.50+0.04 (+1.63%)
Close on Nov 13, 2026Market cap $56.87MP/E –Yield –
Boundless Bio operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Boundless Bio's operating cash flow for the twelve months ending Sep 30, 2026 was -$56.93M. For fiscal 2025 it was -$46.66M.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$46.66M | – |
| FY2024 | Dec 31, 2024 | -$60.84M | – |
| FY2023 | Dec 31, 2023 | -$46.86M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$10.88M | – |
| Q2 FY2026 | Jun 30, 2026 | -$20.97M | – |
| Q1 FY2026 | Mar 31, 2026 | -$14.97M | – |
| Q4 FY2025 | Dec 31, 2025 | -$10.11M | – |
| Q3 FY2025 | Sep 30, 2025 | -$10.20M | – |
| Q2 FY2025 | Jun 30, 2025 | -$11.83M | – |
| Q1 FY2025 | Mar 31, 2025 | -$14.53M | – |
| Q4 FY2024 | Dec 31, 2024 | -$15.56M | – |
| Q3 FY2024 | Sep 30, 2024 | -$13.27M | – |
| Q2 FY2024 | Jun 30, 2024 | -$16.24M | – |
| Q1 FY2024 | Mar 31, 2024 | -$15.78M | – |
| Q4 FY2023 | Dec 31, 2023 | -$11.69M | – |
| Q3 FY2023 | Sep 30, 2023 | -$12.19M | – |
| Q2 FY2023 | Jun 30, 2023 | -$10.89M | – |
| Q1 FY2023 | Mar 31, 2023 | -$12.09M | – |
See a number that looks wrong?